Comparison of the effects of adenosine and nifedipine in pulmonary hypertension

Department of Pharmacy Practice, University of Illinois, Chicago.

The hemodynamic effects of intravenously administered adenosine, a potent vasodilator, were examined in 15 patients with pulmonary hypertension. All patients were given adenosine, 50 micrograms/kg per min, increased by 50 micrograms/kg per min at 2 min intervals to a maximum of 500 micrograms/kg per min or until the development of untoward side effects. The patients were then given oral nifedipine, 20 mg every hour, until a greater than or equal to 20% decrease in pulmonary vascular resistance or systemic hypotension occurred. The administration of maximal doses of adenosine, 256 +/- 46 micrograms/kg per min, produced a 2.4% reduction in pulmonary artery pressure (p = NS), a 37% decrease in pulmonary vascular resistance (p less than 0.001) and a 57% increase in cardiac index (p less than 0.001). The administration of maximally effective doses of nifedipine (91 +/- 36 mg) produced a 15% reduction in the mean pulmonary artery pressure (p less than 0.05), a 24% decrease in pulmonary vascular resistance (p less than 0.01) and an 8% increase in cardiac index (p = NS). There was a significant correlation (r = 0.714, p = 0.01) between the reduction in pulmonary vascular resistance that resulted from adenosine administration and that achieved with the administration of nifedipine. Six patients had substantial reductions in pulmonary vascular resistance with adenosine but not with nifedipine. Thus, adenosine is an effective vasodilator in patients with pulmonary hypertension and can be used for safe and rapid assessment of vasodilator reserve in these patients.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				H. Gupta, G. Ghimire, and R. Naeije The value of tools to assess pulmonary arterial hypertension Eur. Respir. Rev., December 1, 2011; 20(122): 222 - 235. [Abstract] [Full Text] [PDF]

				S. Rich Future of Clinical Trials for Pulmonary Hypertension Circulation, June 28, 2011; 123(25): 2919 - 2921. [Full Text] [PDF]

				M. Delcroix, N. W. Morrell, M. Abramowicz, O. Sitbon, A. Boonstra, N. Galie, E. Grunig, P. Herve, R. C. Trembath, A. J. Peacock, et al. Pulmonary arterial hypertension: genetics, reversibility testing and follow-up Pulmonary Vascular Pathology: a Clinical Update, June 28, 2010; 33 - 56. [Abstract] [Fulltext] [PDF]

				Z-C. Jing, X. Jiang, Z-Y. Han, X-Q. Xu, Y. Wang, Y. Wu, H. Lv, C-R. Ma, Y-J. Yang, and J-L. Pu Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension Eur. Respir. J., June 1, 2009; 33(6): 1354 - 1360. [Abstract] [Full Text] [PDF]

				V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1573 - 1619. [Full Text] [PDF]

				Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association Circulation, April 28, 2009; 119(16): 2250 - 2294. [Full Text] [PDF]

				H. A. Ghofrani, M. W. Wilkins, and S. Rich Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension Circulation, September 9, 2008; 118(11): 1195 - 1201. [Abstract] [Full Text] [PDF]

				T. Thenappan, S. J. Shah, S. Rich, and M. Gomberg-Maitland A USA-based registry for pulmonary arterial hypertension: 1982 2006 Eur. Respir. J., December 1, 2007; 30(6): 1103 - 1110. [Abstract] [Full Text] [PDF]

				L. J. Rubin and D. B. Badesch Evaluation and Management of the Patient with Pulmonary Arterial Hypertension Ann Intern Med, August 16, 2005; 143(4): 282 - 292. [Abstract] [Full Text] [PDF]

				O. Sitbon, M. Humbert, X. Jais, V. Ioos, A. M. Hamid, S. Provencher, G. Garcia, F. Parent, P. Herve, and G. Simonneau Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension Circulation, June 14, 2005; 111(23): 3105 - 3111. [Abstract] [Full Text] [PDF]

				D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 35S - 62S. [Abstract] [Full Text] [PDF]

				E. Bossone, G. Paciocco, D. Iarussi, A. Agretto, A. Iacono, B. W. Gillespie, and M. Rubenfire The Prognostic Role of the ECG in Primary Pulmonary Hypertension Chest, February 1, 2002; 121(2): 513 - 518. [Abstract] [Full Text] [PDF]

				G. Paciocco, F.J. Martinez, E. Bossone, E. Pielsticker, B. Gillespie, and M. Rubenfire Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension Eur. Respir. J., April 1, 2001; 17(4): 647 - 652. [Abstract] [Full Text] [PDF]

				M. J. Ricciardi, E. Bossone, D. S. Bach, W. F. Armstrong, and M. Rubenfire Echocardiographic Predictors of an Adverse Response to a Nifedipine Trial in Primary Pulmonary Hypertension: Diminished Left Ventricular Size and Leftward Ventricular Septal Bowing Chest, November 1, 1999; 116(5): 1218 - 1223. [Abstract] [Full Text] [PDF]

				A. Y. Saadjian, F. Paganelli, M. L. Reynaud Gaubert, S. Levy, and R. P. Guieu Adenosine plasma concentration in pulmonary hypertension Cardiovasc Res, July 1, 1999; 43(1): 228 - 236. [Abstract] [Full Text] [PDF]

				M. J. Ricciardi, B. P. Knight, F. J. Martinez, and M. Rubenfire Inhaled nitric oxide in primary pulmonary hypertension: A safe and effective agent for predicting response to nifedipine J. Am. Coll. Cardiol., October 1, 1998; 32(4): 1068 - 1073. [Abstract] [Full Text] [PDF]

				J. Sandoval, J. Gaspar, T. Pulido, E. Bautista, M. L. Martinez-Guerra, M. Zeballos, A. Palomar, and A. Gomez Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension: A therapeutic alternative for patients nonresponsive to vasodilator treatment J. Am. Coll. Cardiol., August 1, 1998; 32(2): 297 - 304. [Abstract] [Full Text] [PDF]

				J. P. Donnelly, D. M. Raffel, B. L. Shulkin, J. R. Corbett, E. L. Bove, R. S. Mosca, and T. J. Kulik Resting coronary flow and coronary flow reserve in human infants after repair or palliation of congenital heart defects as measured by positron emission tomography J. Thorac. Cardiovasc. Surg., January 1, 1998; 115(1): 103 - 110. [Abstract] [Full Text] [PDF]

				A. S. Malik, S. Warshafsky, and S. Lehrman Meta-analysis of the Long-term Effect of Nifedipine for Pulmonary Hypertension Arch Intern Med, March 24, 1997; 157(6): 621 - 625. [Abstract] [PDF]

				D.J. Williamson, C. Hayward, P. Rogers, L.L. Wallman, A.D. Sturgess, R. Penny, and P.S. Macdonald Acute Hemodynamic Responses to Inhaled Nitric Oxide in Patients With Limited Scleroderma and Isolated Pulmonary Hypertension Circulation, August 1, 1996; 94(3): 477 - 482. [Abstract] [Full Text]

				D. A. Fullerton, S. D. Jones, F. L. Grover, and R. C. McIntyre Jr Adenosine Effectively Controls Pulmonary Hypertension After Cardiac Operations Ann. Thorac. Surg., April 1, 1996; 61(4): 1118 - 1123. [Abstract] [Full Text]